Skip to content

Nestle to buy Aimmune Therapeutics for $2.6B

August 31, 2020

Nestle’s (OTCPK:NSRGY) Health Science division (NHSc) has entered into a definitive agreement to acquire peanut allergy treatment maker Aimmune Therapeutics (NASDAQ:AIMT).

Under the terms of the merger agreement, Nestle’s wholly owned subsidiary, Société des Produits Nestlé S.A. (SPN), will commence a cash tender offer to acquire all outstanding common shares of Aimmune that are not already owned by NHSc for $34.50/share in cash (174% premium to closing price of $12.60 as on August 28), representing a total enterprise value of ~2.6B.

NHSc currently has a total investment of $473M in Aimmune, an approximately 25.6% equity ownership stake. Initial investment of $145M was made in November 2016, followed by further investments of $30M in February 2018, $98M in November 2018 and $200M in January 2020.

The transaction is expected to close in Q4.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: